PMS-DIGOXIN TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

DIGOXIN

Saadav alates:

PHARMASCIENCE INC

ATC kood:

C01AA05

INN (Rahvusvaheline Nimetus):

DIGOXIN

Annus:

0.125MG

Ravimvorm:

TABLET

Koostis:

DIGOXIN 0.125MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/250/500/1000

Retsepti tüüp:

Prescription

Terapeutiline ala:

CARDIOTONIC AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0107281006; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2009-12-01

Toote omadused

_ _
_pms-DIGOXIN (digoxin) _
_Page 1 of 51_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-DIGOXIN
Digoxin Tablets
Tablets, 0.0625 mg, 0.125 mg and 0.25 mg, Oral
C.S.D.
Digoxin Oral Solution
Solution, 0.05 mg/mL, Oral
C.S.D.
Cardiotonic Glycoside
PHARMASCIENCE INC.
6111 Royalmount Avenue, Suite 100
Montréal, QC, Canada
H4P 2T4
Date of Initial Authorization:
NOV 23, 2022
Submission Control Number: 268869
_ _
_pms-DIGOXIN (digoxin) _
_Page 2 of 51_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 5
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 6
4.4
Administration
.......................................................................................................
10
4.5
Missed Dose
..........................................................................................................
10
5
OVERDOSAGE
..